Novel controlled-release Lemna-derived IFN-α2b (Locteron): Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial

Journal of Interferon and Cytokine Research

Volumn 28, Issue 2, 2008, Pages 113-122

  De Leede, Leo G J ^a   Humphries, John E ^b   Bechet, Anne C ^a   Van Hoogdalem, Ewoud J ^a   Verrijk, Ruud ^a   Spencer, David G ^b  

^a OctoPlus NV   (Netherlands)

^b Biolex Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA2B INTERFERON; LOCTERON; MICROSPHERE; NEOPTERIN; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INJECTION SITE REACTION; INTESTINE SOUND; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PLANT LEMMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SORE THROAT; VOMITING;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HEPATITIS C; HUMANS; INJECTIONS; INTERFERON ALFA-2B; INTERFERONS; MALE; MICROSPHERES; MIDDLE AGED; NEOPTERIN; RECOMBINANT PROTEINS;

HEPATITIS C VIRUS; LEMNA;

EID: 39449113296     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0073     Document Type: Article

References (31)

1. Bagheri H, Fouladi A, Barange K, Lapeyre-Mestre M, Payen JL, Montastruc JL, Vinel JP. 2004. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 24:1546-1553.
2. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM. 2006. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44:671-678.
3. Bonetti A, Kim S. 1993. Pharmacokinetics of an extended-release human interferon alpha-2b formulation. Cancer Chemother Pharmacol 33:258-261.
4. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Ciappina V, Patruno S, Filice G. 2005. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antiviral Ther 10:201-205.
5. Caliceti P. 2004. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 36 (Suppl 3):S334-339.
6. Formann E, Jessner W, Bennett L, Ferenci P. 2003. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 10:271-276.
7. Fried MW. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36:S237-244.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
9. Gasdaska JR, Spencer D, Dickey L. 2003. Advantages of therapeutic protein production in the aquatic plant Lemna. Bioproc J Mar/Apr:50-56.
10. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. 2000a. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data; Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68:556-567.
11. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP; The Hepatitis C Intervention Therapy Group. 2000b. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32:647-653.
12. Harris JM, Martin NE, Modi M. 2001. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
13. Hughes CA, Shafran SD. 2006. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 40:74-82.
14. Kowdley KV. 2005. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 39:S3-8.
15. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
16. Manns MP. 2004. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 33:S11-24.
17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
18. McHutchison JG, Fried MW. 2003. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 7:149-161.
19. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C; Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
20. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK. 2002. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061-1069.
21. Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL. 2006. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 13:457-465.
22. Mohl S, Winter G. 2004. Continuous release of rh-interferon alpha-2a from triglyceride matrices. J Control Release 97:67-78.
23. Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y. 2004. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 47:4897-4904.
24. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus; International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
25. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, Zampaglione N. 1987. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 27:432-435.
26. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C; The Swedish Study Group. Lancet 351:83-87.
27. van Dijkhuizen-Radersma R, Hesseling SC, Kaim PE, de Groot K, Bezemer JM. 2002. Biocompatibility and degradation of poly(etherester) microspheres: in vitro and in vivo evaluation. Biomaterials 23:4719-4729.
28. van Dijkhuizen-Radersma R, Métairie S, Roosma JR, de Groot K, Bezemer JM. 2005. Controlled release of proteins from degradable poly(ether-ester) multiblock copolymers. J Control Release 101:175-186.
29. van Dijkhuizen-Radersma R, Roosma JR, Kaim P, Métairie S, Péters FL, de Wijn J, Zijlstra PG, de Groot K, Bezemer JM. 2003. Biodegradable poly(ether-ester) multiblock copolymers for controlled release applications. J Biomed Mater Res A 67:1294-1304.
30. Yamagata Y, Iga K, Ogawa Y. 2000. Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. J Control Release 63:319-329.
31. Zhou S, Deng X, He S, Li X, Jia W, Wei D, Zhang Z, Ma J. 2002. Study on biodegradable microspheres containing recombinant interferon-alpha-2a. J Pharm Pharmacol 54:1287-1292.